>

Samuel Moed - Bristol Myers President

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>BMY</div>
BMY -- USA Stock  

0.45 Dividend

  President
Mr. Samuel J. Moed is Senior Vice President Strategic Planning and Analysis of BristolMyers Squibb Co. He served as 2005 to 2010 Senior Vice President Worldwide Strategy and Operations 2010 to 2012 Senior Vice President Strategy.
Age: 51  President Since 2012      
212 546-4020  www.bms.com

Samuel Moed Latest Insider Activity

Management Efficiency

The company has 25.8 B in debt with debt to equity (D/E) ratio of 159.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Bristol Myers Squibb has Current Ratio of 3.8 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Barton PetersonEli Lilly And Company
2009
Michael RosenblattMerck Company
2009
James BradnerNovartis AG
2016
Adam SchechterMerck Company
2010
Andrew ChengGilead Sciences
2018
Leon WangAstrazeneca PLC
2019
Kirsten LundJurgensenPfizer
2016
Anne WhiteEli Lilly And Company
2018
Andre WyssNovartis AG
2016
Mirian GraddickWeirMerck Company
2009
Laurie OlsonPfizer
2017
Iskra ReicAstrazeneca PLC
2019
Mark MallonAstrazeneca PLC
2016
Joseph WolkJohnson Johnson
2018
Ruud DobberAstrazeneca PLC
2019
Albert BourlaPfizer
2020
Lidia FonsecaPfizer
2019
John YoungPfizer
2019
Freda LewisHallPfizer
2010
Jan LundbergEli Lilly And Company
2010
Michael HarringtonEli Lilly And Company
2019

Company Summary

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 30000 people.Bristol Myers Squibb Company (BMY) is traded on BATS Exchange in USA. It is located in 430 E. 29th Street 14th Floor, New York, NY 10016, United States and employs 30,000 people. Bristol Myers is listed under Pharmaceutical Products category by Fama And French industry classification.

Bristol Myers Squibb Leadership Team

Ann Powell, Chief Human Resource Officer, Senior Vice PresidentView
Togo West, Independent DirectorView
Karen Vousden, Independent DirectorView
Adam Dubow, Senior Vice President Chief Compliance Officer and Ethics OfficerView
Michael Bonney, DirectorView
Alan Lacy, Independent DirectorView
Robert Bertolini, Independent DirectorView
Jose Baselga, Independent DirectorView
Charles Bancroft, Chief Financial Officer, Executive Vice President - Global Business OperationsView
Gerald Storch, Independent DirectorView
Louis Schmukler, Senior Vice President, President - Global Product Development and SupplyView
Michael Grobstein, Independent DirectorView
Christopher Boerner, Executive Vice President and Chief Commercial OfficerView
Phyllis Yale, DirectorView
John Elicker, Senior Vice President - Corporate Affairs and Investor RelationsView
David Elkins, Executive Vice President and Chief Financial Officer Member of the Leadership TeamView
Anne Nielsen, Senior Vice President Chief Compliance and Ethics OfficerView
Karen Santiago, Senior Vice President, Corporate ControllerView
Rupert Vessey, Executive Vice President Research and Early Development Member of the Leadership TeamView
Giovanni Caforio, Chairman of the Board, Chief Executive OfficerView
Vicki Sato, Lead Independent DirectorView
Emmanuel Blin, Senior Vice President Chief Strategy OfficerView
Nadim Ahmed, Executive Vice President and President - HematologyView
Joseph Caldarella, Senior Vice President Corporate ControllerView
Julia Haller, DirectorView
Laurie Glimcher, Independent DirectorView
Murdo Gordon, Executive Vice President Chief Commercial OfficerView
Lamberto Andreotti, Executive Chairman, Officer, Ex-Officio Member of Audit Committee, Ex-Officio Member of Committee on Directors and Corporate Governance and Ex-Officio Member of Compensation and Management Devel. CommitteeView
Joseph Eid, Senior Vice President and Head of Global Medical Affairs Member of the Leadership TeamView
Thomas Lynch, Chief Scientific Officer, Executive Vice PresidentView
Lewis Campbell, Independent DirectorView
Dinesh Paliwal, Independent DirectorView
Theodore Samuels, Independent DirectorView
Samuel Moed, Senior Vice President - Strategic Planning and AnalysisView
Matthew Emmens, Independent DirectorView
Ann Judge, Chief Human Resource Officer, Senior Vice President Member of the Leadership TeamView
Sandra Leung, Executive Vice President, General CounselView
Paul Autenried, Chief Information Officer, Senior Vice PresidentView
Samit Hirawat, Executive Vice President Chief Medical Officer, Global Drug Development Member of the Leadership TeamView
Francis Cuss, Executive Vice President Chief Scientific OfficerView
Paul Biondi, Senior Vice President, Head of Strategy & Business DevelopmentView
Kathryn Metcalfe, Executive Vice President - Corporate Affairs Member of the Leadership TeamView
Peter Arduini, Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Eli Lilly And. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page